Evidence map›Paper›PMID 35150913›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post-mass drug ad ministration surveillance in American Samoa.

Angela M Cadavid Restrepo, Katherine Gass, Kimberly Y Won, Meru Sheel, Keri Robinson, Patricia M Graves, Saipale Fuimaono, Colleen L Lau

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Anti-filarial antibodies are sensitive indicators of lymphatic filariasis transmission and enable identification of high-risk populations and hotspots.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Angela M Cadavid RestrepoSchool of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Australia; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia. Electronic address: a.cadavidrestrepo@uq.edu.au.
Katherine GassNeglected Tropical Diseases Support Center, Task Force for Global Heath, Decatur, Georgia, United States of America.
Kimberly Y WonCenters for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, Georgia, United States of America.
Meru SheelNational Centre for Epidemiology and Population Health, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.
Keri RobinsonCenters for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, Georgia, United States of America.
Patricia M GravesCollege of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia.
Saipale FuimaonoDepartment of Health, Pago Pago, American Samoa, United States of America.
Colleen L LauSchool of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Australia; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.
Australian National University · AUCenters for Disease Control and Prevention · USAmerican Samoa Government · ASJames Cook University · AUThe Task Force for Global Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnder the Global Programme to Eliminate Lymphatic Filariasis (LF), American Samoa conducted 7 rounds of mass drug administration (MDA) between 2000 and 2006. The territory passed transmission assessment surveys (TASs) in 2011 (TAS-1) and 2015 (TAS-2). In 2016, the territory failed TAS-3, indicating resurgence. This study aims to determine if antibodies (Abs) may have provided a timelier indication of LF resurgence in American Samoa.

methodsWe examined school-level antigen (Ag) and Ab status (presence/absence of Ag- and Ab-positive children) and prevalence of single and combined Ab responses to Wb123, Bm14, and Bm33 Ags at each TAS. Pearson chi-square test and logistic regression were used to examine associations between school-level Ab prevalence in TAS-1 and TAS-2 and school-level Ag status in TAS-3.

resultsSchools with higher prevalence of Wb123 Ab in TAS-2 had higher odds of being Ag-positive in TAS-3 (odds ratio [OR] 24.5, 95% confidence interval [CI] 1.2-512.7). Schools that were Ab-positive for WB123 plus Bm14, Bm33, or both Bm14 and Bm33 in TAS-2 had higher odds of being Ag-positive in TAS-3 (OR 16.0-24.5).

conclusionAbs could provide earlier signals of resurgence and enable a timelier response. The promising role of Abs in surveillance after MDA and decision making should be further investigated in other settings.

Indexed as

Elephantiasis, FilarialAmerican SamoaAnimalsAntibodies, HelminthAntigens, HelminthChildHumansPharmaceutical PreparationsWuchereria bancroftiAntibodies, HelminthAntigens, HelminthPharmaceutical PreparationsAmerican SamoaAntifilarial antibodiesLymphatic filariasisLymphatic filariasis resurgencePost–mass drug administrationTransmission assessments surveys

Identifiers

PMID35150913
PMCPMC8948089
OpenAlexW4225694338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.